Fulcrum Therapeutics
FULC
61 hedge funds and large institutions have $374M invested in Fulcrum Therapeutics in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
86% more capital invested
Capital invested by funds: $201M → $374M (+$173M)
30% more funds holding
Funds holding: 47 → 61 (+14)
2.52% more ownership
Funds ownership: 72.05% → 74.58% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$11.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.86M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.63M |
| 5 |
PA
Perceptive Advisors
New York
|
+$4.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.17M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.93M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$692K |
| 4 |
CTB
Country Trust Bank
Bloomington,
Illinois
|
-$315K |
| 5 |
JP Morgan Chase
New York
|
-$259K |
FULC Hedge Fund Activity: Q2 2020 in Review
61 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2020, worth a combined $374M — up 86% from $201M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new FULC positions and 4 closed out — a net gain of 14 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $13.9M. The largest seller was Millennium Management, cutting an estimated $2.17M.
- 61 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2020, up from 47 in Q1 2020.
- Funds reported $374M of Fulcrum Therapeutics stock for Q2 2020, up 86% quarter-over-quarter.
- 18 funds opened new Fulcrum Therapeutics positions in Q2 2020 and 4 closed out, a net change of +14 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2020 was EcoR1 Capital, an estimated $13.9M added.
- The largest Fulcrum Therapeutics seller in Q2 2020 was Millennium Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q2 2020.